Autism is a heterogeneous disorder with a poorly understood biological basis. Some children with autism harbor plasma autoantibodies that target brain proteins. Similarly, some mothers of children with autism produce antibodies specific to autism that target pairs of fetal brain proteins at 37/73 and 39/73 kDa. We explored the relationship between the presence of brain-specific autoantibodies and several behavioral characteristics of autism in 277 children with an autism spectrum disorder and 189 typically developing age-matched controls. Further, we used maternal autoantibody data to investigate potential familial relationships for the production of brain-directed autoantibodies. We demonstrated by Western blot that autoantibodies specific for a 45 kDa cerebellar protein in children were associated with a diagnosis of autism (p = 0.017) while autoantibodies directed towards a 62 kDa protein were associated with the broader diagnosis of autism spectrum disorder (ASD) (p = 0.043). Children with such autoantibodies had lower adaptive (p = 0.0008) and cognitive function (p = 0.005), as well as increased aberrant behaviors (p < 0.05) compared to children without these antibodies. No correlation was noted for those mothers with the most specific pattern of anti-fetal brain autoantibodies and children with the autoantibodies to either the 45 or 62 kDa bands. Collectively, these data suggest that antibodies towards brain proteins in children are associated with lower adaptive and cognitive function as well as core behaviors associated with autism. It is unclear whether these antibodies have direct pathologic significance, or if they are merely a response to previous injury. Future studies are needed to determine the identities of the protein targets and explore their significance in autism.
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Introduction
Autism spectrum disorders are a group of psychological conditions that manifest in early childhood. These disorders are characterized by widespread abnormalities of social interactions and communication, as well as restricted interests and repetitive behavior (American Psychiatric Association, 1994; Lord et al., 2000a; World Heath Organization, 2006) . The autism phenotype is heterogeneous with regard to behavioral severity and disease onset (Meilleur and Fombonne, 2009; Micali et al., 2004; Ozonoff et al., 2010; Stefanatos, 2008) . Autism spectrum disorders are clinically defined, and current diagnosis is based entirely on behavioral testing and analysis of medical and developmental history (Le Couteur et al., 2008; Lord et al., 1994 Lord et al., , 2000b . The pathology and etiology of these disorders remain unclear; though emerging evidence suggests that genetic, neurological, environmental, and immune factors are likely involved (Pardo and Eberhart, 2007) .
The neurobiology of autism spectrum disorders has been explored through various imaging techniques and examination of post-mortem samples. Data suggest that abnormal brain growth, altered neuronal migration and connectivity, and/or changes in minicolumnar organization may be involved (Pardo and Eberhart, 2007) . Subtle differences have been reported in brain regions including the cerebral cortex, limbic structures, and cerebellum (Pardo and Eberhart, 2007) . Overall, the neurological basis of autism spectrum disorders remains poorly understood, largely due to difficulties in obtaining quality post-mortem samples and a lack of information on early brain development. Further, the factors that cause neurological abnormalities are largely undefined.
Immune dysregulation has been noted among individuals with an autism spectrum disorder and their family members (Ashwood
